Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Syndax Pharmaceuticals excels in Q4, poised for growth in 2023

Syndax Pharmaceuticals demonstrated strong financial and developmental performance in Q4 2022, with promising advancements in Revumenib and axatilimab.
While facing challenges in FDA considerations and safety data optimization, Syndax is well-positioned to capitalize on opportunities in expanding market reach and strategic partnerships.
The company's clear financial guidance, enrollment progress, and strategic initiatives underscore a positive outlook for future growth and commercial success.

Syndax Pharmaceuticals reports strong financials and advances key drug candidates

Syndax Pharmaceuticals shows strong financial position with a focus on pivotal drug candidates.
Analyst interest in drug efficacy and trial progress highlights market engagement.
Challenges include financial losses, specific patient response data, and trial design considerations.
Opportunities lie in growth potential, market expansion, and strategic partnerships.

Syndax Pharmaceuticals reports Q2 progress with focus on innovative treatments

Syndax Pharmaceuticals' Q2 performance reflects financial stability with a focus on promising trial outcomes.
Strengths lie in innovative drug development, market reach strategies, and a differentiated treatment approach.
Challenges include regulatory hurdles, commercialization decisions, and managing financial resources effectively.
Opportunities arise from upcoming data releases, market penetration plans, and showcasing treatment differentiators.

Syndax Pharmaceuticals reports positive trial data and financial stability

Syndax Pharmaceuticals showcases strong performance in pivotal trials, supported by a solid financial position and a focus on expanding into new indications.
Challenges include enrollment diversity and breakthrough therapy designation, but opportunities lie in market expansion and personalized treatment approaches.
Overall, Syndax is well-positioned to advance its pipeline and deliver innovative therapies for leukemia patients, with a focus on quality data and strategic growth.

Syndax Pharmaceuticals advances key drugs towards potential approvals and commercialization

Syndax Pharmaceuticals made notable progress in 2023, positioning itself for potential drug approvals and commercialization in 2024.
While facing challenges in market competition and regulatory processes, the company's strategic collaborations and pipeline advancements signal a proactive growth trajectory.
With a strong financial position, ongoing clinical trials, and a focus on refining dosing strategies, Syndax is poised to capitalize on market opportunities and drive innovation in oncology.

Syndax Pharmaceuticals reports strong Q1 performance and readies for transformative year ahead

Syndax Pharmaceuticals showcased strong performance, financial stability, and commercial readiness in their Q1 2024 Earnings Call, highlighting a promising outlook for the company's future.
While facing challenges in patient response rates and market adoption, Syndax's robust pipeline, strategic financial planning, and commercial expertise position it well for growth and success.
With opportunities for retreatment strategies, regulatory expedited pathways, and new market engagements, Syndax is poised for a transformative year ahead, leveraging its strengths to drive innovation and market expansion.

Syndax Pharmaceuticals excels in Q3 with FDA approvals and strategic partnerships

Syndax Pharmaceuticals delivered a strong performance in Q3 2024, marked by FDA approvals and strategic partnerships. Their financial position is robust, setting the stage for successful commercialization and future pipeline advancements. While challenges exist in a competitive landscape, the company's innovative pipeline and market opportunities position them for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B.

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W.

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Designation to SNDX-5613, the Company's highly selective oral menin inhibitor, for the treatment of acute myeloid leukemia (AML).

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia

WALTHAM, Mass., Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 3,802,144 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 645,000 additional shares, and to certain investors, pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001.

Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 shares of its common stock, and to certain investors pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001.

Syndax Announces Pricing of $75.3 Million Public Offering

WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Syndax Announces Proposed Public Offering of Common Stock

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were featured at the American Society of Hematology (ASH) Annual Meeting.

Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial

WALTHAM, Mass., Dec. 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) despite two or more prior lines of therapy.

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody.

Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript

WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2021.

Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.

Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021

WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021.

Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting

The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Incyte

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's axatilimab. Related Content:   Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs.

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate

The stock price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) increased by over 14% today. This is why it happened.

SNDX Stock: Why It Increased Today

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

WALTHAM, Mass., Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members with the appointment of Martin H.

Syndax Appoints Martin H. Huber, M.D.

WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences: A fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 9:30 a.m.

Syndax Announces Participation at Three Upcoming Investor Conferences

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call Transcript

Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates

WALTHAM, Mass., Aug. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2021.

News for Syndax Pharmaceuticals Stock (SNDX)